Lixte Biotechnology Holdings Inc (LIXT) is not a strong buy for a beginner, long-term investor at this time. The technical indicators show a bearish trend, there are no significant trading trends or positive news catalysts, and the company's financial performance remains weak with no revenue and negative net income. Given the lack of positive signals and the investor's preference for long-term stability, it is better to hold off on investing in this stock.

Technical Analysis

The MACD is slightly positive but contracting, suggesting weak momentum. RSI is neutral at 39.213, indicating no clear overbought or oversold conditions. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its support level of 2.864, with resistance at 3.246. Overall, the technical indicators suggest a bearish trend.

Positive Catalysts

NULL identified. No recent news or significant insider/hedge fund activity.

Neutral/Negative Catalysts

also declined by 0.56%. The company's financials show no revenue and negative net income, with EPS declining 25% YoY.

Financial Performance

In Q3 2025, the company reported no revenue growth (0.00% YoY). Net income improved by 105.95% YoY but remains negative at -2,030,765. EPS dropped by 25% YoY to -0.33. Gross margin remains at 0. The financial performance is weak overall.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast LIXT stock price to rise

Buy

Hold

Sell

Current: 2.890

Low

Averages

High